How much do you agree with the following statements? *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
The activity presented balanced, evidence-based content free of commercial bias.	The activity presented balanced, evidence-based content free of commercial bias. - Strongly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Disagree	The activity presented balanced, evidence-based content free of commercial bias. - Slightly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Neither	The activity presented balanced, evidence-based content free of commercial bias. - Slightly agree	The activity presented balanced, evidence-based content free of commercial bias. - Agree	The activity presented balanced, evidence-based content free of commercial bias. - Strongly agree
The presenter(s) used an effective teaching strategy.	The presenter(s) used an effective teaching strategy. - Strongly disagree	The presenter(s) used an effective teaching strategy. - Disagree	The presenter(s) used an effective teaching strategy. - Slightly disagree	The presenter(s) used an effective teaching strategy. - Neither	The presenter(s) used an effective teaching strategy. - Slightly agree	The presenter(s) used an effective teaching strategy. - Agree	The presenter(s) used an effective teaching strategy. - Strongly agree
The presentation slides / digital materials / resources and handouts were high quality.	The presentation slides / digital materials / resources and handouts were high quality. - Strongly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Disagree	The presentation slides / digital materials / resources and handouts were high quality. - Slightly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Neither	The presentation slides / digital materials / resources and handouts were high quality. - Slightly agree	The presentation slides / digital materials / resources and handouts were high quality. - Agree	The presentation slides / digital materials / resources and handouts were high quality. - Strongly agree
The content was relevant to / useful for my professional practice.	The content was relevant to / useful for my professional practice. - Strongly disagree	The content was relevant to / useful for my professional practice. - Disagree	The content was relevant to / useful for my professional practice. - Slightly disagree	The content was relevant to / useful for my professional practice. - Neither	The content was relevant to / useful for my professional practice. - Slightly agree	The content was relevant to / useful for my professional practice. - Agree	The content was relevant to / useful for my professional practice. - Strongly agree
The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care.	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Neither	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly agree
The overall quality of the educational activity was excellent.	The overall quality of the educational activity was excellent. - Strongly disagree	The overall quality of the educational activity was excellent. - Disagree	The overall quality of the educational activity was excellent. - Slightly disagree	The overall quality of the educational activity was excellent. - Neither	The overall quality of the educational activity was excellent. - Slightly agree	The overall quality of the educational activity was excellent. - Agree	The overall quality of the educational activity was excellent. - Strongly agree

The activity successfully achieved its learning objectives by enhancing my ability to: *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties.	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Strongly disagree	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Disagree	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Slightly disagree	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Neither	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Slightly agree	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Agree	Describe the context and need for advanced training in medical management of chemical, biological, radiological and nuclear (CBRN) casualties. - Strongly agree
Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes.	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Strongly disagree	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Disagree	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Slightly disagree	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Neither	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Slightly agree	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Agree	Apply the CRESS (consciousness, respirations, eyes, secretions, skin) algorithm into the identification of toxidromes. - Strongly agree
Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties.	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Strongly disagree	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Disagree	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Slightly disagree	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Neither	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Slightly agree	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Agree	Outline the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach to the treatment of chemical, biological, radiological, and nuclear (CBRN) casualties. - Strongly agree
Identify useful reference materials for the management of CBRN casualties.	Identify useful reference materials for the management of CBRN casualties. - Strongly disagree	Identify useful reference materials for the management of CBRN casualties. - Disagree	Identify useful reference materials for the management of CBRN casualties. - Slightly disagree	Identify useful reference materials for the management of CBRN casualties. - Neither	Identify useful reference materials for the management of CBRN casualties. - Slightly agree	Identify useful reference materials for the management of CBRN casualties. - Agree	Identify useful reference materials for the management of CBRN casualties. - Strongly agree
Analyze the pathophysiology of nerve agent exposure.	Analyze the pathophysiology of nerve agent exposure. - Strongly disagree	Analyze the pathophysiology of nerve agent exposure. - Disagree	Analyze the pathophysiology of nerve agent exposure. - Slightly disagree	Analyze the pathophysiology of nerve agent exposure. - Neither	Analyze the pathophysiology of nerve agent exposure. - Slightly agree	Analyze the pathophysiology of nerve agent exposure. - Agree	Analyze the pathophysiology of nerve agent exposure. - Strongly agree
Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes.	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Strongly disagree	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Disagree	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Slightly disagree	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Neither	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Slightly agree	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Agree	Differentiate the clinical effects of nerve agent exposure based on the specific agent, dose, and route of exposure to predict patient outcomes. - Strongly agree
Manage nerve agent casualties at the Role 3/4, and intensive care settings.	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Strongly disagree	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Disagree	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Slightly disagree	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Neither	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Slightly agree	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Agree	Manage nerve agent casualties at the Role 3/4, and intensive care settings. - Strongly agree
Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases.	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Strongly disagree	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Disagree	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Slightly disagree	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Neither	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Slightly agree	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Agree	Critique the standard treatment protocols for nerve agent-induced seizures and propose alternative, evidence-based polytherapy regimens for refractory cases. - Strongly agree
Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies.	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Strongly disagree	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Disagree	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Slightly disagree	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Neither	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Slightly agree	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Agree	Design a flexible pharmaceutical strategy for a mass-casualty incident based on standard U.S. medical countermeasures with contingency options and NATO-ally formularies. - Strongly agree
Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack.	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Strongly disagree	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Disagree	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Slightly disagree	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Neither	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Slightly agree	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Agree	Assess the complex challenges of managing CBRN casualties,868 comparing and contrasting historical events, such as the Iran-Iraq War and the Tokyo subway attack. - Strongly agree
Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy.	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Strongly disagree	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Disagree	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Slightly disagree	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Neither	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Slightly agree	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Agree	Justify continuous dosing of anticholinergics, oximes, and anticonvulsants for a severely poisoned patient, adapting the regimen based on the patient's evolving clinical status and response to therapy. - Strongly agree
Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication.	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Strongly disagree	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Disagree	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Slightly disagree	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Neither	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Slightly agree	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Agree	Evaluate the fundamental principles for identifying and treating a casualty with a metabolic agent intoxication. - Strongly agree
Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine.	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Strongly disagree	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Disagree	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Slightly disagree	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Neither	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Slightly agree	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Agree	Consider a differential diagnosis for a patient presenting with undifferentiated cellular hypoxia, evaluating the clinical toxidromes of various metabolic poisons, including cyanide, hydrogen sulfide, and phosphine. - Strongly agree
Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms.	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Strongly disagree	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Disagree	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Slightly disagree	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Neither	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Slightly agree	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Agree	Justify the administration of specific, and sometimes unconventional, antidotes for intoxications from agents like hydrogen sulfide and hydrogen selenide, based on an understanding of their complex toxicological mechanisms. - Strongly agree
Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties.	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Strongly disagree	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Disagree	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Slightly disagree	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Neither	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Slightly agree	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Agree	Compare & contrast the distinct timelines of centrally-acting agents with peripherally-acting agents, predicting the onset of delayed pulmonary edema and justifying appropriate disposition for exposed casualties. - Strongly agree
Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries.	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Strongly disagree	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Disagree	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Slightly disagree	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Neither	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Slightly agree	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Agree	Analyze a treatment plan for a casualty with combined vesicant and pulmonary injuries. - Strongly agree
Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury.	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Strongly disagree	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Disagree	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Slightly disagree	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Neither	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Slightly agree	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Agree	Evaluate the indications and risks of topical, intradermal, intra-arterial, and nebulized calcium for a patient with severe hydrofluoric acid burns and inhalation injury. - Strongly agree
Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination.	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Strongly disagree	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Disagree	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Slightly disagree	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Neither	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Slightly agree	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Agree	Appraise the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination. - Strongly agree
Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol.	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Strongly disagree	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Disagree	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Slightly disagree	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Neither	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Slightly agree	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Agree	Consider an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol. - Strongly agree
Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents.	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Strongly disagree	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Disagree	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Slightly disagree	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Neither	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Slightly agree	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Agree	Evaluate the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents. - Strongly agree
Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone.	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Strongly disagree	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Disagree	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Slightly disagree	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Neither	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Slightly agree	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Agree	Calculate appropriate infusion rates for atropine, pralidoxime, and naloxone. - Strongly agree
Evaluate commonly used infusion equipment options within the context of this scenario.	Evaluate commonly used infusion equipment options within the context of this scenario. - Strongly disagree	Evaluate commonly used infusion equipment options within the context of this scenario. - Disagree	Evaluate commonly used infusion equipment options within the context of this scenario. - Slightly disagree	Evaluate commonly used infusion equipment options within the context of this scenario. - Neither	Evaluate commonly used infusion equipment options within the context of this scenario. - Slightly agree	Evaluate commonly used infusion equipment options within the context of this scenario. - Agree	Evaluate commonly used infusion equipment options within the context of this scenario. - Strongly agree
Prepare a Cyanokit™ infusion.	Prepare a Cyanokit™ infusion. - Strongly disagree	Prepare a Cyanokit™ infusion. - Disagree	Prepare a Cyanokit™ infusion. - Slightly disagree	Prepare a Cyanokit™ infusion. - Neither	Prepare a Cyanokit™ infusion. - Slightly agree	Prepare a Cyanokit™ infusion. - Agree	Prepare a Cyanokit™ infusion. - Strongly agree
Consider alternative solutions to standard nerve agent antidote formulations.	Consider alternative solutions to standard nerve agent antidote formulations. - Strongly disagree	Consider alternative solutions to standard nerve agent antidote formulations. - Disagree	Consider alternative solutions to standard nerve agent antidote formulations. - Slightly disagree	Consider alternative solutions to standard nerve agent antidote formulations. - Neither	Consider alternative solutions to standard nerve agent antidote formulations. - Slightly agree	Consider alternative solutions to standard nerve agent antidote formulations. - Agree	Consider alternative solutions to standard nerve agent antidote formulations. - Strongly agree
Prepare standardized pralidoxime and atropine infusions.	Prepare standardized pralidoxime and atropine infusions. - Strongly disagree	Prepare standardized pralidoxime and atropine infusions. - Disagree	Prepare standardized pralidoxime and atropine infusions. - Slightly disagree	Prepare standardized pralidoxime and atropine infusions. - Neither	Prepare standardized pralidoxime and atropine infusions. - Slightly agree	Prepare standardized pralidoxime and atropine infusions. - Agree	Prepare standardized pralidoxime and atropine infusions. - Strongly agree
Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products.	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Strongly disagree	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Disagree	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Slightly disagree	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Neither	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Slightly agree	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Agree	Analyze the DoDs multi-layered medical countermeasure (MCM) acquisition strategy, differentiating between the development of novel produces and the rapid repurposing of existing products. - Strongly agree
Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats.	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Strongly disagree	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Disagree	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Slightly disagree	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Neither	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Slightly agree	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Agree	Evaluate the strategic advantages of the Countering Emerging Threats – Rapid Acquisition and Investigation of Drugs for Repurposing (CET-RAIDR) program by justifying its use of FDA-approved drugs to rapidly inform Clinical Practice Guidelines (CPGs) for novel threats. - Strongly agree
Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows.	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Strongly disagree	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Disagree	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Slightly disagree	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Neither	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Slightly agree	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Agree	Synthesize information from the Joint Program Manager (JPM) CBRN Medical product pipeline with the stated goals of the Chemical Biological Defense Program (CBDP) to predict future shifts in military medical readiness and formulate potential integration points for these new capabilities into existing clinical and operational workflows. - Strongly agree
Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms.	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Strongly disagree	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Disagree	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Slightly disagree	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Neither	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Slightly agree	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Agree	Differentiate between likely CBRN threat agents, using the Clinical Practice Guideline’s syndromic algorithms. - Strongly agree
Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment.	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Strongly disagree	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Disagree	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Slightly disagree	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Neither	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Slightly agree	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Agree	Appreciate an integrated management plan for a suspected bio incident in a prolonged casualty care or mass casualty (MASCAL) operational environment. - Strongly agree
Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty.	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Strongly disagree	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Disagree	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Slightly disagree	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Neither	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Slightly agree	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Agree	Appraise the supporting evidence, regulatory status, and population-specific factors while evaluating competing medical countermeasures and prophylaxis strategies for a presented biological casualty. - Strongly agree
Identify and treat severe nerve agent seizures and inhalational chemical injury.	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Strongly disagree	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Disagree	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Slightly disagree	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Neither	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Slightly agree	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Agree	Identify and treat severe nerve agent seizures and inhalational chemical injury. - Strongly agree
Practice preparation of medication infusions.	Practice preparation of medication infusions. - Strongly disagree	Practice preparation of medication infusions. - Disagree	Practice preparation of medication infusions. - Slightly disagree	Practice preparation of medication infusions. - Neither	Practice preparation of medication infusions. - Slightly agree	Practice preparation of medication infusions. - Agree	Practice preparation of medication infusions. - Strongly agree
Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios.	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Strongly disagree	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Disagree	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Slightly disagree	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Neither	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Slightly agree	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Agree	Distinguish endemic vs intentional disease in potentially weaponized biological agent scenarios. - Strongly agree
Describe radiation injury patterns to allow for appropriate triage and treatment.	Describe radiation injury patterns to allow for appropriate triage and treatment. - Strongly disagree	Describe radiation injury patterns to allow for appropriate triage and treatment. - Disagree	Describe radiation injury patterns to allow for appropriate triage and treatment. - Slightly disagree	Describe radiation injury patterns to allow for appropriate triage and treatment. - Neither	Describe radiation injury patterns to allow for appropriate triage and treatment. - Slightly agree	Describe radiation injury patterns to allow for appropriate triage and treatment. - Agree	Describe radiation injury patterns to allow for appropriate triage and treatment. - Strongly agree
Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment.	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Strongly disagree	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Disagree	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Slightly disagree	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Neither	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Slightly agree	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Agree	Utilize the Chemical Patient Protective Wrap to safely transport a patient through a contaminated environment. - Strongly agree
Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards.	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Strongly disagree	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Disagree	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Slightly disagree	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Neither	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Slightly agree	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Agree	Explain the patterns of signs and symptoms of various tropical poisonous and venomous hazards. - Strongly agree
Associate various tropical hazards with appropriate management strategies and targeted treatments.	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Strongly disagree	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Disagree	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Slightly disagree	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Neither	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Slightly agree	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Agree	Associate various tropical hazards with appropriate management strategies and targeted treatments. - Strongly agree
Describe anticipated illness and risks during evacuation and care.	Describe anticipated illness and risks during evacuation and care. - Strongly disagree	Describe anticipated illness and risks during evacuation and care. - Disagree	Describe anticipated illness and risks during evacuation and care. - Slightly disagree	Describe anticipated illness and risks during evacuation and care. - Neither	Describe anticipated illness and risks during evacuation and care. - Slightly agree	Describe anticipated illness and risks during evacuation and care. - Agree	Describe anticipated illness and risks during evacuation and care. - Strongly agree
Identify limitations, complications, and adverse events of various treatment modalities.	Identify limitations, complications, and adverse events of various treatment modalities. - Strongly disagree	Identify limitations, complications, and adverse events of various treatment modalities. - Disagree	Identify limitations, complications, and adverse events of various treatment modalities. - Slightly disagree	Identify limitations, complications, and adverse events of various treatment modalities. - Neither	Identify limitations, complications, and adverse events of various treatment modalities. - Slightly agree	Identify limitations, complications, and adverse events of various treatment modalities. - Agree	Identify limitations, complications, and adverse events of various treatment modalities. - Strongly agree
Identify emerging chemical and biological threats across the globe.	Identify emerging chemical and biological threats across the globe. - Strongly disagree	Identify emerging chemical and biological threats across the globe. - Disagree	Identify emerging chemical and biological threats across the globe. - Slightly disagree	Identify emerging chemical and biological threats across the globe. - Neither	Identify emerging chemical and biological threats across the globe. - Slightly agree	Identify emerging chemical and biological threats across the globe. - Agree	Identify emerging chemical and biological threats across the globe. - Strongly agree
Assess the efficacy of existing antidotes and countermeasures against emerging threats.	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Strongly disagree	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Disagree	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Slightly disagree	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Neither	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Slightly agree	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Agree	Assess the efficacy of existing antidotes and countermeasures against emerging threats. - Strongly agree
Describe the role for novel antidotes and countermeasures against emerging threats.	Describe the role for novel antidotes and countermeasures against emerging threats. - Strongly disagree	Describe the role for novel antidotes and countermeasures against emerging threats. - Disagree	Describe the role for novel antidotes and countermeasures against emerging threats. - Slightly disagree	Describe the role for novel antidotes and countermeasures against emerging threats. - Neither	Describe the role for novel antidotes and countermeasures against emerging threats. - Slightly agree	Describe the role for novel antidotes and countermeasures against emerging threats. - Agree	Describe the role for novel antidotes and countermeasures against emerging threats. - Strongly agree
Discuss relevant medical management of human cases exposed to non-traditional agents.	Discuss relevant medical management of human cases exposed to non-traditional agents. - Strongly disagree	Discuss relevant medical management of human cases exposed to non-traditional agents. - Disagree	Discuss relevant medical management of human cases exposed to non-traditional agents. - Slightly disagree	Discuss relevant medical management of human cases exposed to non-traditional agents. - Neither	Discuss relevant medical management of human cases exposed to non-traditional agents. - Slightly agree	Discuss relevant medical management of human cases exposed to non-traditional agents. - Agree	Discuss relevant medical management of human cases exposed to non-traditional agents. - Strongly agree

What do you anticipate changing or how will you apply what you learned in your professional practice? *

How will you apply what you learned when working with providers of other disciplines or members of your interprofessional healthcare team? *

What barriers, if any, do you see to implementing these changes? *

Please provide feedback on your experience navigating this website and completing the CE process. *

Based on your educational needs, what topics would you like to see addressed in future educational activities? *

Please discuss any additional concerns or comments about this program and indicate whether the program met your expectations. *

attestation checkbox *

I completed this educational activity independently and in its entirety.

Leave this field blank